Subscribe To

Price Alert Latest News Economic Calendar News

CORT / Corcept Therapeutics Incorporated (CORT) Q4 2022 Earnings Call Transcript

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Bill Guyer - Chief Development Officer Sean Maduck - President of Endocrinology Division Conference Call Participants Raymond Wu - Ladenburg Thalmann Dennis Ding - Jefferies Greg Fraser - Truist Arthur He - H.C. Wainwright Operator Greetings, and welcome to the Corcept Therapeutics Conference Call. Read More

Demo Live Account See Partner Details

Content Topics

Corcept

Therapeutics

Incorporated

CORT

2022

Earnings

Call

cort

Transcript

Stock

Posted: Feb 28 2023, 19:59

Author Name: Seeking Alpha

CORT News

By Zacks Investment Research
November 2, 2023

Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View

Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023.

By GlobeNewsWire
October 25, 2023

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter fi

By Seeking Alpha
August 26, 2023

Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade)

Corcept Therapeutics' equity stock shows promising investment prospects with the resolution of its Korlym overhang and strong financial performance. T

By Zacks Investment Research
August 25, 2023

Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio

Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its pro

By Zacks Investment Research
August 3, 2023

Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View

Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023,

By Zacks Investment Research
May 4, 2023

Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance

Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guid

By Seeking Alpha
May 3, 2023

Corcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Call Transcript

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Fi

By Zacks Investment Research
May 3, 2023

Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compare

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.